HIV post-exposure prophylaxis: Difference between revisions

No edit summary
Line 21: Line 21:
#Basic (2-Drug)
#Basic (2-Drug)
##Tenofovir-Emtricitabine 300mg/200mg (Truvada): 1 tab PO QD
##Tenofovir-Emtricitabine 300mg/200mg (Truvada): 1 tab PO QD
##OR, Zidovudine-Lamivudine 300mg/150mg (Combivir): 1 tab PO BID
##OR, Zidovudine-Lamivudine 300mg/150mg (Combivir)^: 1 tab PO BID
#Expanded (3-Drug)
#Expanded (3-Drug)
##Ritonavir-Lopinavir (Kaletra)
##Ritonavir-Lopinavir 50mg/200mg(Kaletra): 2 tabs PO BID
###PLUS tenofovir-emtricitabine OR zidovudine-lamivudine


##High risk exposures
^Prefered in pregnancy
##Basic regimen + protease inhibitor (e.g. indinavir or nelfinavir)


==High Risk==
==High Risk==

Revision as of 04:47, 24 November 2012

Workup

  1. Td
  2. Hepatitis B PEP for non-vaccinated
    1. Hepatitis B immunoglobulin and/or vaccine
  3. Source labs
    1. Rapid HIV, hep pannel, RPR?
  4. Exposed labs
    1. Rapid HIV, hep pannel, RPR?
  5. Consider HIV PEP
    1. CBC, C7, LFTs, Icon if considering HIV PEP

^Currently no PEP for Hep C

HIV PEP

  • ~79% transmission reduction
  • Initiate ASAP (goal = 1-2 hours)
  • >36 hours: normally deferred, unless particularly high risk
  • Common side-effects = constitutional, gastrointestinal

Specific Regimens (CDC)

  1. Basic (2-Drug)
    1. Tenofovir-Emtricitabine 300mg/200mg (Truvada): 1 tab PO QD
    2. OR, Zidovudine-Lamivudine 300mg/150mg (Combivir)^: 1 tab PO BID
  2. Expanded (3-Drug)
    1. Ritonavir-Lopinavir 50mg/200mg(Kaletra): 2 tabs PO BID
      1. PLUS tenofovir-emtricitabine OR zidovudine-lamivudine

^Prefered in pregnancy

High Risk

Source

  1. Symptomatic HIV/AIDS
  2. Acute seroconversion
  3. High viral load

Exposure

  1. Deep injuries
  2. Visible blood on device
  3. Injuries sustained placing a catheter in a vein/artery

See Also

Occupational Exposure

Source

8/07 DONALDSON

Retrieved from "https://www.wikem.org/w/index.php?title=HIV_post-exposure_prophylaxis&oldid=10580"